The Preparation of Convencent Plasma and Recruiting of Donors during the COVID-19 Pandemic
- 作者: Kostin A.I.1, Petrikov S.S.1, Borovkova N.V.1, Doronina N.V.1, Godkov M.A.1, Simarova I.B.1,2, Mayorova O.A.3, Momotyuk K.S.3, Danilec V.V.4, Yarotskaya I.A.4, Gincburg A.L.5, Hripun A.I.6, Logunov D.Y.5, Dolschikova I.V.5, Mazus A.I.7, Vasilyeva E.Y.8, Vasin E.A.2, Ganchin V.V.9, Nikonov E.L.6, Pinchuk A.V.1,10, Bulanov A.Y.2, Lisenko M.A.2
-
隶属关系:
- N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow Department of Healthcare
- 52th City Clinical Hospital
- Blood Center O.K. Gavrilova Moscow Department of Healthcare
- City Clinical Hospital M.P. Konchalovskiy
- National Research Center of Epidemiology and Microbiology N.F. Gamaleya of the Ministry of Health of the Russian Federation
- Moscow Department of Healthcare
- Moscow City AIDS Prevention and Control Center of the City Health Department
- City Clinical Hospital I.V. Davydovsky
- Autonomous non-commercial organizations “Center of Analytical Development of the Social Sector”
- Research Institute for Healthcare Organization and Medical Management
- 期: 卷 75, 编号 5S (2020)
- 页面: 446-454
- 栏目: INFECTIOUS DISEASES: CURRENT ISSUES
- URL: https://journals.rcsi.science/vramn/article/view/125735
- DOI: https://doi.org/10.15690/vramn1432
- ID: 125735
如何引用文章
全文:
详细
Background. The pandemic of the new coronavirus infection has challenged the medical community for quickly finding and implementing effective methods of treatment. In the absence of a vaccine or specific therapy with proven effectiveness, the usage of convalescent plasma can be the one of perspective methods. An important aspect of this technology is the efficient and safe preparation of convalescent plasma. To date, in the world literature there are practically no publications about donor recruitment and the specifics of the preparation of convalescent plasma.
Purpose of the research. Presentation of the experience of organizing a workflow for recruiting donors and stockpiling of convalescent plasma with a high titer of virus-neutralizing antibodies to SARS-CoV-2.
Methods. The analysis of the work of the Blood Service of the Moscow Department of Health for stockpiling of COVID-19 convalescent plasma has been executed. In total it has been stockpiled 1240 doses. The normative documentation has been developed by a working group on the basis of the current federal legislation of Russian federation and been approved by the Moscow Department of Health. The titer of neutralizing antibodies (VNA) has been determined as the basic method for assessing the immunological viability of convalescent plasma. The main characteristics of donors, the characteristics of the disease course, the results of preliminary testing for the presence of specific antibodies by ELISA and CLIA methods has been compared with VNA titers in the stockpiled convalescent plasma.
Results. Due to a Moscow Health Department’s order No. 325 dated 01.04.2020 (a basic local regulatory document) it has been developed a regulation for the stockpiling, examination, storage, safety and transfering of fresh frozen pathogen-reduced plasma of COVID-19 convalescent donors to medical organizations of the Moscow Health Department. For arranging an interaction with donors it has been created a call-center. For effective preliminary selection, it has been formed a donor characteristics list, which has been combined with screening of specific antibodies by ELISA and CLIA methods.
Conclusions. Developed a system of recruiting donors and procurement process of convalescent plasma for treatment СOVID-19, which includes the necessary regulations, algorithms for the selection and recruitment of donors, the registry of donors and recipients, algorithms, efficiency and safety of convalescent plasma.
作者简介
Alexandr Kostin
N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow Department of Healthcare
Email: kostinai@sklif.mos.ru
ORCID iD: 0000-0001-7542-851X
SPIN 代码: 7119-8871
MD, PhD
俄罗斯联邦, MoscowSergey Petrikov
N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow Department of Healthcare
Email: petrikov@mail.ru
ORCID iD: 0000-0003-3292-8789
MD, PhD, Professor, Corresponding Member of the RAS
俄罗斯联邦, MoscowNataliya Borovkova
N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow Department of Healthcare
Email: Borovkova@mail.ru
ORCID iD: 0000-0002-8897-7523
SPIN 代码: 9339-2800
MD, PhD
俄罗斯联邦, MoscowNatal’ya Doronina
N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow Department of Healthcare
Email: Doronina@mail.ru
ORCID iD: 0000-0002-4242-2645
俄罗斯联邦, Moscow
Mihail Godkov
N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow Department of Healthcare
Email: Godcov@mail.ru
ORCID iD: 0000-0002-0854-8076
MD, PhD
俄罗斯联邦, MoscowIrina Simarova
N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow Department of Healthcare; 52th City Clinical Hospital
Email: rirab@mail.ru
ORCID iD: 0000-0002-9042-3917
MD
俄罗斯联邦, Moscow; MoscowOlga Mayorova
Blood Center O.K. Gavrilova Moscow Department of Healthcare
Email: MOE@yandex.ru
SPIN 代码: 8059-1987
MD, PhD, Professor
俄罗斯联邦, MoscowKira Momotyuk
Blood Center O.K. Gavrilova Moscow Department of Healthcare
Email: kira.s.momotyuk@gmail.com
ORCID iD: 0000-0002-6836-8368
MD, PhD
俄罗斯联邦, MoscowVioletta Danilec
City Clinical Hospital M.P. Konchalovskiy
Email: buldoc68@mail.ru
ORCID iD: 0000-0003-4605-8315
俄罗斯联邦, Moscow
Irina Yarotskaya
City Clinical Hospital M.P. Konchalovskiy
Email: yarotskayia@zdrav.mos.ru
俄罗斯联邦, Moscow
Alexandr Gincburg
National Research Center of Epidemiology and Microbiology N.F. Gamaleya of the Ministry of Health of the Russian Federation
Email: info@gamaleya.org
ORCID iD: 0000-0003-1769-5059
SPIN 代码: 7626-0373
PhD in Biology, Academician of the RAS
俄罗斯联邦, MoscowAlexey Hripun
Moscow Department of Healthcare
Email: info@gamaleya.org
ORCID iD: 0000-0001-6765-2837
SPIN 代码: 5340-4305
MD, PhD
俄罗斯联邦, MoscowDenis Logunov
National Research Center of Epidemiology and Microbiology N.F. Gamaleya of the Ministry of Health of the Russian Federation
Email: logunov@gamaleya.org
ORCID iD: 0000-0003-4035-6581
SPIN 代码: 4000-4717
PhD in Biology, Corresponding Member of the RAS
俄罗斯联邦, MoscowInna Dolschikova
National Research Center of Epidemiology and Microbiology N.F. Gamaleya of the Ministry of Health of the Russian Federation
Email: dolzhikova@gamaleya.org
ORCID iD: 0000-0003-2548-6142
SPIN 代码: 1462-7079
PhD in Biology
俄罗斯联邦, MoscowAlexey Mazus
Moscow City AIDS Prevention and Control Center of the City Health Department
Email: mazus@mail.ru
ORCID iD: 0000-0002-4110-3941
MD, PhD
俄罗斯联邦, MoscowElena Vasilyeva
City Clinical Hospital I.V. Davydovsky
Email: Vasilyeva@yandex.ru
SPIN 代码: 9515-1566
MD, PhD, Professor
俄罗斯联邦, MoscowEvgenij Vasin
52th City Clinical Hospital
Email: spectrum48@yandex.ru
ORCID iD: 0000-0002-1439-9476
Analyst
俄罗斯联邦, MoscowVladimir Ganchin
Autonomous non-commercial organizations “Center of Analytical Development of the Social Sector”
Email: GanchinVV@zdrav.mos.ru
ORCID iD: 0000-0001-9138-6479
SPIN 代码: 9058-7791
俄罗斯联邦, Moscow
Evgeniy Nikonov
Moscow Department of Healthcare
Email: NikonovEL@mos.zdrav.ru
ORCID iD: 0000-0002-5231-711X
SPIN 代码: 5618-1533
俄罗斯联邦, Moscow
Alexey Pinchuk
N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow Department of Healthcare; Research Institute for Healthcare Organization and Medical Management
Email: PinchukAV@mos.zdrav.ru
ORCID iD: 0000-0001-9019-9567
SPIN 代码: 8875-2456
俄罗斯联邦, Moscow; Moscow
Andrey Bulanov
52th City Clinical Hospital
编辑信件的主要联系方式.
Email: buldoc68@mail.ru
ORCID iD: 0000-0001-6999-8145
MD, PhD
俄罗斯联邦, 3 Pehotnaya str., 123182, MoscowMar’yana Lisenko
52th City Clinical Hospital
Email: gkb52@zdrav.mos.ru
ORCID iD: 0000-0001-6010-7975
MD, PhD
俄罗斯联邦, Moscow参考
- Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733 doi: https://doi.org/10.1056/NEJMoa2001017
- Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269. doi: https://doi.org/10.1038/s41586-020-2008-3
- Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi: https://doi.org/10.1038/s41586-020-2012-7
- Baud D, Qi X, Nielsen-Saines K, et al. Real estimates of mortality following COVID-19 infection. Lancet Infect. Dis. 2020;20(7):773. doi: https://doi.org/10/1016/S1473-3099(20)30195-X
- Pei S, Yuan X, Zhang ZZ, et al. Convalescent Plasma to Treat COVID-19: Chinese Strategy and Experiences. Med Rxiv. 2020:Preprint. doi: https://doi.org/10.1101/2020.04.07.20056440
- Official website of Moscow Mayor of Sergey Sobyanin [Electronic resource]. Available from: https://www.sobyanin.ru/podtverzhden-sluchai-novoi-koronavirusnoi-infektsii
- Стопкоронавирус.рф — официальный интернет-ресурс для информирования населения по вопросам коронавируса (COVID-19) [Электронный ресурс]. Available from: https://стопкоронавирус.рф.
- Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599–609. doi: https://doi.org/10.7326/0003-4819-145-8-200610170-00139
- Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80–90. doi: https://doi.org/10.1093/infdis/jiu396
- Cheng Y, Wong R, Soo Y, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–46. doi: https://doi.org/10.1007/s10096-004-1271-9
- Sullivan HC, Roback JD. Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic. Transfus Med Rev. 2020;34(3):145–150. doi: https://doi.org/ 10.1016/j.tmrv.2020.04.001
- Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400. doi: https://doi.org/10.1016/S1473-3099(20)30141-9
- Dzik S. COVID-19 Convalescent Plasma: Now Is the Time for Better Science. Transfus Med Rev. 2020;34(3):141–144. doi: https://doi.org/10.1016/j.tmrv.2020.04.002
- Epstein J, Burnouf T. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. Vox Sang. 2020;115(6):485–487. doi: https://doi.org/10.1111/vox.12939
- Tiberghien P, de Lamballerie X, Morel P, et al. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang. 2020;115(6):488–494. doi: https://doi.org/10.1111/vox.12926
- Joyner M, Wright RS, Fairweather D, et al. Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients. Med Rxiv. 2020:Preprint. doi: https://doi.org/10.1101/2020.05.12.20099879
- Thompson C, Grayson N, Paton R. et al. Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors — a pilot study of the value of serology to determine population exposure. 2020:Preprint. Med Rxiv. doi: https://doi.org/10.1101/2020.04.13.20060467
- Randomised Evaluation of COVID-19 Therapy (RECOVERY). 2020. Oxford, United Kingdom [Electronic resource]. Available from: https://www.recoverytrial.net/
- U.S. Food and Drug Administration. Recommendations for Investigational COVID-19 Convalescent Plasma. May 1, 2020 [Electronic resource]. Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma
- Joyner MJ, Bruno KA, Klassen SA, et al. Mayo Clinical Protocol. 2020; 95. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin Proc. 2020;95(9):1888–1897. doi: https://doi.org/10.1016/j.mayocp.2020.06.028
- Инструкция по иммунизации доноров стафилококковым анатоксином и проведению плазмафереза для получения антистафилококковой плазмы. Утверждена заместителем Министра здравоохранения СССР 2 августа 1977 г. № 10-8/49. [Instrukciya po immunizacii donorov stafilokokkovym anatoksinom i provedeniyu plazmafereza dlya polucheniya antistafilokokkovoj plazmy. Utverzhdena zamestitelem Ministra zdravoohraneniya SSSR 2 avgusta 1977 g. № 10-8/49. (In Russ.)]
- Хватов В.Б. Иммунопрофилактика и иммунотерапия // Профилактика внутрибольничной инфекции. Руководство для врачей / под ред. Е.Н. Семиной, А.С. Ковалевой. — М.: Рапор, 1993. — 307 с. [Hvatov VB. Immunoprofilaktika i immunoterapiya. Profilaktika vnutribol’nichnoj infekcii. Rukovodstvo dlya vrachej. pod red. E.N. Seminoj, A.S. Kovalevoj. Moscow: Rapor; 1993. 307 p. (In Russ.)]
- Бодрова Г.Н. Получение и оценка иммунологической активности антитоксической антисинегнойной плазмы: автореф. дис. … канд. мед. наук. — М., 1997. [Bodrova GN. Poluchenie i ocenka immunologicheskoj aktivnosti antitoksicheskoj antisinegnojnoj plazmy: dis. … kand. med. nauk. Moscow; 1997. (In Russ.)]
- Булава Г.В. Иммунопрофилактика и иммунотерапия гнойно-септических осложнений у пострадавших с проникающими ранениями груди и живота: автореф. дис. … д-ра мед. наук. — М., 2003. [Bulava GV. Immunoprofilaktika i immunoterapiya gnojno-septicheskih oslozhnenij u postradavshih s pronikayushchimi raneniyami grudi i zhivota: avtoref. dis. … d-ra med. nauk. Moscow; 2003. (In Russ.)]
- Биткова Е.Е. Оценка специфической антимикробной активности иммунных плазм: автореф. дис. … канд. мед. наук. — М., 2007. [Bitkova EE. Ocenka specificheskoj antimikrobnoj aktivnosti immunnyh plazm: avtoref. dis. … kand. med. nauk. Moscow; 2007. (In Russ.)]
- Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(5):460–470. doi: https://doi.org/10.1001/jama.2020.10044
- Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490–9496. doi: https://doi.org/10.1073/pnas.2004168117
- Zhang B, Liu S, Tan T, et al. Treatment with Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Chest. 2020;158(1):e9–e13. doi: https://doi.org/10.1016/j.chest.2020.03.039
- Ahn JY, Sohn Y, Lee SH, et al. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. J Korean Med Sci. 2020;35(14):e149. doi: https://doi.org/10.3346/jkms.2020.35.e14
- Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma. JAMA. 2020;323(16):1582–1589. doi: https://doi.org/10.1001/jama.2020.4783
- Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221–224. doi: https://doi.org/10.1038/s41586-020-2179-y
- Worldometer Licensing is a provider of global COVID-19 [Electronic resource]. Available from: https://www.worldometers.info/coronavirus/
- EU CCP database — Covid-19 convalescent plasma collection and transfusion in the EU. Available from: https://ec.europa.eu/health/blood_tissues_organs/covid-19_en
- An EU programme of COVID-19 convalescent plasma collection and transfusion. Available from: https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/guidance_plasma_covid19_en.pdf
- Young MK. The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella and measles. Hum Vaccin Immunother. 2019;15(9):2060–2065. doi: https://doi.org/10.1080/21645515.2019.1621148
- Gonik B. Passive immunization: the forgotten arm of immunologically based strategies for disease containment. Am J Obstet Gynecol. 2011;205(5):444.e1–444.e6. doi: https://doi.org/10.1016/j.ajog.2011.06.076.
补充文件
